Galderma
CLICK HERE if you are a Consumer
Roll Over for Important Safety Information

Patient Satisfaction


Metrogel Patient Satisfaction

‡ Calculations based on average wholesale price, assuming 0.5 g/application(s) per day for 30 days.
§ At week 15, stinging and burning scores were comparable.
Line 2: Cost for 30-day supply
Line 3: Formulary coverage (tier 2)
Line 4: Significant reduction in inflammatory lesions
Line 5: Significant change in erythema scores from baseline at week 15
Line 6: Pregnancy category B
Line 7: HSA-3 vehicle
Line 9: Significantly bothered by drug side effects
Line 10: Significantly higher incidence of stinging
and burning at week 3
Line 11: Potential for hypopigmentation

HELP YOUR PATIENTS
 FIND A DERMATOLOGIST
(Enter the first 3 digits of your zip code)

IMPORTANT SAFETY INFORMATION

METROGEL® (metronidazole) Gel, 1% is a nitroimidazole indicated for the topical treatment of inflammatory lesions of rosacea. The most common adverse reactions that have been reported with the topical use of METROGEL® 1% are nasopharyngitis, upper respiratory tract infections and headaches, as well as dryness, scaling, itching, and stinging. Transient redness, metallic taste, tingling or numbness of extremities and nausea have also been reported with the topical use of metronidazole. METROGEL®1% therapy should be reevaluated if these symptoms occur. Caution should be used when prescribing metronidazole products for patients with blood dyscrasia, and patients using blood thinning agents such as coumarin or warfarin may experience prolonged prothrombin times. METROGEL® 1% is contraindicated in patients with a history of hypersensitivity to metronidazole or any other ingredient in the formulation.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.